期刊
JOURNAL OF NEUROSCIENCE RESEARCH
卷 92, 期 12, 页码 1611-1620出版社
WILEY
DOI: 10.1002/jnr.23456
关键词
isocitrate dehydrogenase; IDH1; IDH2; glioma; 2-hydroxyglutarate; prognostic marker; predictive marker
资金
- Ministry of Health of the Czech Republic [NT 13581]
- Technology Agency of the Czech Republic [TE02000058]
- Internal Grant Agency of Palacky University [LF_2014_019]
- Operational Program Research and Development for Innovations [CZ.1.05/2.1.00/01.0030]
Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identification of possible targets for glioma therapy. Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations have been shown to be promising biomarkers for monitoring disease prognosis and predicting the response to treatment. This review summarizes recent findings in this field. Web of Science, Science Direct, and PubMed online databases were used to search for publications investigating the role of IDH in glioma. References were identified by searching for the keywords IDH1 or IDH2 and glioma and diagnostic or predictive or prognostic in papers published from January, 2008, to April, 2014. Only papers in English were reviewed. Publications available only as an abstract were not included. IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2-hydroxyglutarate (2HG). Although the contradictory positive effect of IDH mutation on prognosis and negative role of 2HG in tumor transformation remain unresolved, the future direction of personalized treatment strategies targeted to glioma development is likely to focus on IDH1/2 mutations. (c) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据